Gain Therapeutics, Inc. Common Stock (GANX)

Etorro trading 970x250

About Gain Therapeutics, Inc. Common Stock

Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland. Address: 4800 Hampden Lane, Bethesda, MD, United States, 20814

Gain Therapeutics, Inc. Common Stock News and around…

Latest news about Gain Therapeutics, Inc. Common Stock (GANX) common stock and company :

Aggregate Insider Buying Remains Elevated For A Third Week $AMH
23 May, 2022 FinancialContent

In another challenging week for the markets where the Nasdaq dropped nearly 4%, insiders once again significantly stepped up their ...

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference
18 May, 2022 Yahoo! Finance

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that the company’s Chief Executive Officer, Eric Richman, will present and host one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place May 23-25 in Mi

Sum Up The Pieces: IWC Could Be Worth $180
18 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $179.75 per unit.

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates
16 May, 2022 Yahoo! Finance

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Recap: Gain Therapeutics Q1 Earnings
16 May, 2022 FinancialContent

Gain Therapeutics (NASDAQ:GANX) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM. Here's what investors need to ...

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
16 May, 2022 Yahoo! Finance

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company’s Lead Program into Clinical Trials BETHESDA, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechno

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium
11 May, 2022 Yahoo! Finance

Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in relevant Gaucher disease (GD) modelsBETHESDA, Md., May 11, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today presen

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
10 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're starting off another busy day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

92 Biggest Movers From Friday
09 May, 2022 FinancialContent

Gainers Sidus Space, Inc. (NASDAQ: SIDU) jumped 51.8% to settle at $2.99 on Friday after the company announced a a memorandum of ...

55 Stocks Moving In Friday's Mid-Day Session
06 May, 2022 FinancialContent

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new ...

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress
06 May, 2022 Yahoo! Finance

Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal ModelsBETHESDA, Md., May 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform to identify novel targets and small molecule treatments, today announced that it presented positive pre-clinical data from its GBA Parkinson’s Disease (PD) program. The results were hig

Cloopen Announced Formation of Independent Special Committee for Internal Investigation
03 May, 2022 Yahoo! Finance

Cloopen Group Holding Limited (NYSE: RAAS) ("Cloopen" or the "Company") today announced that it has formed an independent special committee to investigate certain employee misconduct and transaction irregularities.

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02 May, 2022 Yahoo! Finance

Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
26 Apr, 2022 Yahoo! Finance

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced that Chief Executive Officer Eric Richman will participate in a fireside chat during the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference, and invites investors to partic

Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program
12 Apr, 2022 FinancialContent

Gain Therapeutics Inc(NASDAQ: GANX) haspresented new preclinicaldata from its Parkinson's Disease (PD) program at ...

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
12 Apr, 2022 Yahoo! Finance

Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and survival in relevant neuronal cell modelsBETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today presented new pre-cli

Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022
29 Mar, 2022 FinancialContent

Upgrades According to OTR Global, the prior rating for Illumina Inc (NASDAQ:ILMN) was changed from Mixed to Positive. For the fourth ...

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference
29 Mar, 2022 Yahoo! Finance

Study results demonstrate lead compounds increase GCase protein levels, activity and co-localization in the lysosome, and decrease toxic substrate accumulationBETHESDA, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update
24 Mar, 2022 Yahoo! Finance

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company’s lead program into clinical trials ---Compelling preclinical data presented on lead program GBA1 Parkinson’s Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end --- Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications BETHESDA

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
15 Mar, 2022 FinancialContent

Gain Therapeutics Inc(NASDAQ: GANX) haspresented new preclinical datafrom its Parkinson's and Alzheimer's ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
15 Mar, 2022 FinancialContent

Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market ...

Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
15 Mar, 2022 Yahoo! Finance

Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding Demonstration of in vitro and in vivo functional efficacy in neurodegenerative disease with GCase causality First demonstration of an allosteric regulator with functional activity in both Parkinson’s and Alzheimer’s disease models BETHESDA, Md., March 15, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a

Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
01 Mar, 2022 Yahoo! Finance

- Oppenheimer 32nd Annual Healthcare Conference - - AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - - Krabbe Translational Research Network Meeting - BETHESDA, Md., March 01, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today

Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
08 Feb, 2022 Yahoo! Finance

Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functionsBETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data

Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
04 Feb, 2022 Yahoo! Finance

BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today held its inaugural research and development day webinar. Capitalizing on significant advances in computational biology and drug discovery, the Company has applied its proprietary computational S

52 Biggest Movers From Yesterday
02 Feb, 2022 FinancialContent

Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) ...

34 Stocks Moving In Tuesday's Mid-Day Session
01 Feb, 2022 FinancialContent

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient ...

Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day
31 Jan, 2022 Yahoo! Finance

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the UndruggableBETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced additional details on its R&D Day being held virtually on Friday, February 4, 2022 from 10:00 am

Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences
18 Jan, 2022 Yahoo! Finance

- Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable -- 18th Annual WORLDSymposium –- AD/PD™ 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D Day Event and p

Stocks That Hit 52-Week Lows On Wednesday
12 Jan, 2022 FinancialContent

On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen ...

Gain Therapeutics, Inc. Common Stock (GANX) is a NASDAQ Common Stock listed in , ,

970x250